Finasteride for women: pregnancy risk, results and alternatives

Finasteride must not be used by women who are or may become pregnant: the label lists pregnancy as a contraindication because the drug can cause abnormal genital development in a male fetus. It is also approved for men only, so when a clinician prescribes finasteride to a woman for hair loss, usually after menopause, it is off-label, and the evidence that it works in women is mixed.

Here is what the label says, what the studies in women found, the side effects reported in women, and the treatments clinicians more often use for female pattern hair loss.

Pregnancy comes first

The Propecia label is direct about this. Finasteride is Pregnancy Category X and contraindicated in women who are or may become pregnant. It blocks the making of DHT, a hormone a male fetus needs for normal development of the genitals, and in animal studies it caused abnormal external genitalia in male offspring.

The label also covers exposure without taking it:

• Crushed or broken tablets. Women who are or may become pregnant should not handle them. The coating on intact tablets prevents skin contact during normal handling. If a pregnant woman touches a crushed or broken tablet, she should wash the area with soap and water right away.
• A partner’s semen. The label notes women could be exposed through semen from a male partner taking finasteride, and summarizes a study that measured it.
• Topical products. These have no coating. The FDA’s April 2025 alert warned that compounded topical finasteride carries a greater risk of transfer to others, specifically women, through skin contact.

Breastfeeding is ruled out too. The label says it is not known whether finasteride passes into breast milk, and a 2020 review says it is prohibited during breastfeeding because of the potential risk to a male infant. In one of the studies of younger women below, participants took an oral contraceptive at the same time to prevent pregnancy.

Is finasteride approved for women?

No. The label approves finasteride 1 mg for male pattern hair loss “in MEN ONLY” and says it is not indicated for use in women. Any prescription for a woman’s hair loss is off-label, which means the FDA has not reviewed whether it works or is safe for that use.

The only treatment FDA-approved for female pattern hair loss is topical minoxidil, as the 2020 review notes. Finasteride has been used off-label in women because female and male pattern hair loss share features, but the role of male hormones in female hair loss is less clear, and most women with it have normal hormone levels.

Finasteride in women: what the studies found

Among the studies the 2020 review collected, only one trial of oral finasteride in women used a placebo, and it was negative. Larger doses looked better in studies without a placebo group.

Scroll sideways to see the full table

Two caveats apply to the positive studies. None compared finasteride with a placebo, so some of the improvement could come from time, attention or other treatment. And in the Iorizzo study, the authors said they couldn’t tell whether the benefit came from the higher dose or from the contraceptive, which contains drospirenone, an ingredient with anti-androgen effects. The 2020 review concluded that finasteride may be an alternative for women who don’t respond to minoxidil, and suggested using it in postmenopausal women to avoid the pregnancy risk. Our finasteride 1 mg vs 5 mg guide explains the two tablet strengths.

Finasteride side effects in women

Side effects in women have not been well studied, the 2020 review says, because so few women have taken part in trials. What has been reported:

• 5 mg a day, 87 women, 12 months: 4 women (4.6%) reported headache, irregular periods, dizziness or increased body hair. All were mild and went away; 1 woman stopped because of headache.
• 5 mg a day, 40 postmenopausal women, 18 months: lasting loss of libido in 4 and raised liver enzymes in 1.
• 1 mg a day, 137 postmenopausal women: generally well tolerated; blood DHT fell with no change in other hormones.
• 2.5 mg a day with a contraceptive, 37 women: no adverse reactions reported.

In men, the label lists sexual side effects in trials and postmarketing reports of depression, suicidal thoughts and sexual problems that continued after stopping; see finasteride side effects. The 2020 review’s authors also advise avoiding finasteride in women with a family history of breast cancer, citing its possible effect on the balance of estrogen and testosterone. Tell your clinician about any change in mood right away.

Topical finasteride for women

Topical finasteride is meant to act on the scalp with less effect on the rest of the body. No topical finasteride is FDA-approved, alone or combined with other ingredients, so the products sold in the US are compounded: a compounding pharmacy prepares them, and they aren’t FDA-approved.

The best trial in women is small. In a 24-week double-blind trial of 30 postmenopausal women, 0.25% finasteride added to 3% minoxidil solution thickened hairs more than 3% minoxidil alone, and both groups gained density. No systemic side effects were reported, but blood DHT fell in the finasteride group, showing some of the drug was absorbed. The authors said the combination should be reserved for postmenopausal women.

The FDA’s April 2025 alert counted 32 adverse event reports with compounded topical finasteride from 2019 to 2024, including depression, anxiety and suicidal thoughts, most persisting after stopping. See topical vs oral finasteride for more.

Who might be offered finasteride

Putting the label and the studies together, a clinician who considers finasteride for a woman is most likely to do so when:

• she is past menopause, or otherwise cannot become pregnant,
• topical minoxidil hasn’t worked well enough after a fair trial, and
• she understands the use is off-label and the evidence is mixed.

For women who could become pregnant, one study paired finasteride with an oral contraceptive, and the topical trial authors limited their combination to postmenopausal women.

What clinicians usually try first

Topical minoxidil. The Women’s Rogaine 5% foam is labeled as a hair regrowth treatment for women, used once a day without a prescription. Our minoxidil for women guide covers the trials, the timelines and the off-label low-dose pill.

Spironolactone. This blood pressure and heart medicine blocks androgen effects and is widely used for female pattern hair loss, particularly in women of reproductive age, according to a 2025 trial. It is off-label for hair loss. In that trial, 48 premenopausal women all used 3% minoxidil, and adding spironolactone 100 mg a day for 24 weeks gave moderate to marked improvement in 38% against 9% on placebo; the gain in terminal hair count did not reach statistical significance, and 37.5% on spironolactone had irregular periods. It is not a pregnancy-safe alternative either: the Aldactone label says to avoid it in pregnancy because of the risk to a male fetus, and to check potassium within a week of starting or changing the dose. See spironolactone for hair loss and spironolactone side effects.

What it costs in October 2026

These are prices from online providers that treat women, as of October 2026. Compounded products are prepared by a pharmacy for your prescription and aren’t FDA-approved.

Hers also lists a compounded finasteride and minoxidil serum for postmenopausal women, but we couldn’t confirm its price. Compare every provider that treats women on our best hair loss treatments for women list.

Questions to ask before starting

• Could I become pregnant, and if so, what contraception does this require?
• Has my hair loss been confirmed as female pattern hair loss, and have other causes been checked?
• Have I given topical minoxidil a fair trial first?
• What dose are you proposing, and is it oral or a compounded topical?
• How will we judge whether it is working, and when?

The bottom line

For women, finasteride is off-label, ruled out in pregnancy and breastfeeding, and backed by mixed evidence: a negative placebo-controlled trial at 1 mg and more encouraging but uncontrolled studies at 2.5 to 5 mg. It is mostly considered for postmenopausal women when minoxidil hasn’t been enough. Topical minoxidil remains the approved starting point, and spironolactone is the off-label pill more often used before menopause. More options are on our hair loss hub.